Projects

RNDr. Alena Gábelová, CSc.

International

Finished
  • TEmperature-responsive Nanogels for TArgeted delivery of miCroRNAs in wound heaLing and tissue rEgeneration applicationS
    Program: ERANET
    Duration: 1. 2. 2020 – 31. 1. 2024
  • Strategies to strengthen scientific excellence and innovation capacity for early diagnosis of gastrointestinal cancer
    Program: Horizon 2020
    Duration: 1. 10. 2019 – 30. 6. 2023
  • Establishing an algorithm for the early diagnosis and follow-up of patients with pancreatic neuroendocrine tumors
    Program: ERANET
    Duration: 1. 9. 2019 – 31. 3. 2023
  • Epigenotoxicity of nanomaterials
    Program: Inter-academic agreement
    Duration: 1. 1. 2020 – 31. 12. 2022
  • Targeted combination therapy of colon cancer with therapeutic gene/drug loaded novel dendritic nanocarriers
    Program: Bilateral - other
    Duration: 3. 9. 2018 – 30. 11. 2022
  • Innovative Nanopharmaceuticals: Targeting Breast Cancer Stem Cells by a Novel Combination of Epigenetic and Anticancer Drugs with Gene Therapy
    Program: ERANET
    Duration: 1. 1. 2017 – 30. 6. 2021
  • The Comet assay as a human biomonitoring tool
    Program: COST
    Duration: 1. 4. 2016 – 31. 3. 2020
  • High level Integrated Sensor for Nano Toxicity Screening
    Program: Horizon 2020
    Duration: 1. 4. 2016 – 31. 3. 2019
  • The role of photoactivation and polyphenols in toxity of mixtures of chemical carcinogens
    Program: Inter-academic agreement
    Duration: 1. 1. 2007 – 31. 12. 2009

National

Current
  • Effect of Dietary Supplements on Follicular Fluid in Female Infertility: Mitigating Oxidative Stress
    Program: VEGA
    Duration: 1. 1. 2024 – 31. 12. 2027
  • Innovative approaches to the diagnosis and treatment of pancreatic ductal adenocarcinoma
    Program:
    Duration: 1. 9. 2024 – 30. 6. 2026
Finished
  • Novel renal antisense therapy platform for CKD
    Program: SRDA
    Duration: 1. 8. 2021 – 30. 6. 2025
  • Use of microfluidic systems for risk assessment of xenobiotics
    Program: VEGA
    Duration: 1. 1. 2021 – 31. 12. 2024
  • Preclinical validation of an innovative antisense platform for CML
    Program: SRDA
    Duration: 1. 7. 2020 – 30. 6. 2024
  • Newly syntethized thymol derivatives: relationship between structure and biological activity in colorectal in vitro model.
    Program: VEGA
    Duration: 1. 1. 2020 – 31. 12. 2023
  • Glycoprofiling of proteins present in serum and exosomes for early prostate cancer diagnostics
    Program: Other projects
    Duration: 1. 12. 2019 – 30. 12. 2022
  • New glucoconjugate-based precursors of pharmaceuticals: structure-activity relationship analysis
    Program: VEGA
    Duration: 1. 1. 2018 – 31. 12. 2021
  • Gold nanoparticles: impact of physicochemical properties on distribution, accumulation, and biological response in vivo (BIONANOGOLD)
    Program: SRDA
    Duration: 1. 7. 2017 – 30. 6. 2021
  • Induction of apoptosis by betulinic acid coupled to magnetite nanoparticles in human colorectal cell lines
    Program: VEGA
    Duration: 1. 1. 2017 – 31. 12. 2020
  • Multivalent morpholino-based antisense system for CML
    Program: SRDA
    Duration: 1. 7. 2016 – 30. 6. 2020
  • Mechanisms of gold and magnetic nanoparticle effects on renal cells
    Program: VEGA
    Duration: 1. 1. 2015 – 31. 12. 2018
  • Mechanism of uptake and trafficking of magnetic iron oxide nanoparticles into human tumor and normal (diploid) cells
    Program: VEGA
    Duration: 1. 1. 2013 – 31. 12. 2016
  • Development of SQUID Gradiometric and Susceptometric Methods for Iron Homeostasis Related Bio-Applications
    Program: VEGA
    Duration: 1. 1. 2013 – 31. 12. 2016
  • Implementation of radiobiological research of intensity-modulated proton therapy into clinical oncology practice
    Program: EU Structural Funds Research & Development
    Duration: 20. 10. 2010 – 31. 3. 2014
  • Molecular mechanisms of magnetite nanoparticles interactions due to internalisation and accumulation in cells in vitro
    Program: VEGA
    Duration: 1. 1. 2009 – 31. 12. 2012
  • Centre of Excellence for Translational Research in Molecular medicine
    Program: EU Structural Funds Research & Development
    Duration: 1. 6. 2010 – 31. 5. 2012
  • Center of Excelence for Translational Research in Molecular Medicine
    Program: EU Structural Funds Research & Development
    Duration: 1. 6. 2009 – 31. 5. 2011
  • The role of genotoxic and epigenetic mechanism in tissue and organ specificity of chemical carcinogens, mammaliam cells cultivated in vitro as model systém
    Program: VEGA
    Duration: 1. 1. 2006 – 31. 12. 2008
Employees